Zalasta 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IB/0044/G 
This was an application for a group of variations. 
01/03/2024 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
N/0043 
Minor change in labelling or package leaflet not 
03/02/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10540
Periodic Safety Update EU Single assessment - 
01/12/2022 
n/a 
PRAC Recommendation - maintenance 
/202203 
olanzapine 
N/0041 
Minor change in labelling or package leaflet not 
07/12/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0040 
Minor change in labelling or package leaflet not 
17/05/2021 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IB/0039/G 
This was an application for a group of variations. 
06/04/2021 
n/a 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
Page 2/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
procedure 
IA/0038 
A.4 - Administrative change - Change in the name 
15/06/2020 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/10540
Periodic Safety Update EU Single assessment - 
12/12/2019 
21/02/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201903 
olanzapine 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10540/201903. 
IB/0037/G 
This was an application for a group of variations. 
12/08/2019 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 3/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0035 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/06/2019 
21/02/2020 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
N/0034 
Minor change in labelling or package leaflet not 
19/01/2018 
21/02/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0032 
B.II.b.3.z - Change in the manufacturing process of 
07/12/2017 
n/a 
the finished or intermediate product - Other variation 
IA/0033 
B.II.b.3.a - Change in the manufacturing process of 
24/11/2017 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0031 
C.I.z - Changes (Safety/Efficacy) of Human and 
27/01/2017 
18/05/2017 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
PSUSA/2205/
Periodic Safety Update EU Single assessment - 
01/12/2016 
n/a 
PRAC Recommendation - maintenance 
201603 
olanzapine 
IA/0030/G 
This was an application for a group of variations. 
19/10/2016 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0029 
C.I.z - Changes (Safety/Efficacy) of Human and 
08/07/2016 
18/05/2017 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IAIN/0027 
C.I.8.a - Introduction of or changes to a summary of 
22/07/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IB/0026 
Update of sections 4.4 and 5.1 of the SmPC in order 
05/09/2014 
22/10/2015 
SmPC, 
Labelling and 
PL 
to reflect the level of data available in adolescents 
with bipolar I disorder (manic or mixed episodes) or 
schizophrenia following the completion of a long-
term safety study, to fulfil the requirement laid down 
in Article 46 of the paediatric regulation following the 
same change for the originator. 
In addition the phone number for the local 
representative in UK has been updated and minor 
editorial corrections have been made in all annexes. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0025 
B.I.a.1.z - Change in the manufacturer of AS or of a 
28/02/2014 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
Page 5/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0024/G 
This was an application for a group of variations. 
11/02/2014 
26/08/2014 
SmPC and PL 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
diluted/reconstituted product 
IA/0023 
B.II.b.3.a - Change in the manufacturing process of 
15/11/2013 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0022 
Update of section 4.8 of the SmPC and relevant 
19/08/2013 
26/08/2014 
SmPC, Annex 
section of the PL to include “amnesia, epistaxis, 
II and PL 
abdominal distension, arthralgia, GGT high, uric acid 
high, pyrexia and dysarthria”, as new undesirable 
effects. 
The frequencies of currently labelled undesirable 
effects have also been revised throughout sections 
4.4 and 4.8 of the SmPC and relevant sections of the 
PL. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
N/0021 
Minor change in labelling or package leaflet not 
09/07/2013 
26/08/2014 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0020 
Consequential to the CHMP adoption of a variation to 
26/09/2012 
29/10/2012 
SmPC, Annex 
II, Labelling 
and PL 
the Marketing Authorisation of Zyprexa 
(EMEA/H/C/xxxx/WS/0215), the MAH updated 
section 4.8 of the olanzapine SmPCs to add urinary 
retention as an undesirable effect. The PLs were 
changed in order to reflect this change in the section 
4. 
The product information was updated according to 
version 8 of the QRD template. 
In addition some minor editorial changes were made 
in translations for the countries Czech Republic, 
Germany, Hungary, Norway, Portugal, Italy and 
Spain.  
The MAH also took the opportunity to correct details 
of local representatives. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
R/0019 
Renewal of the marketing authorisation. 
24/05/2012 
26/07/2012 
SmPC, Annex 
Based on the CHMP review of the available information and 
II and PL 
on the basis of a re-evaluation of the benefit risk balance, 
the CHMP is of the opinion that the quality, safety and 
efficacy of this medicinal product continues to be 
adequately and sufficiently demonstrated and therefore 
considered that the benefit risk profile of Zalasta continues 
to be favourable. 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
IA/0018 
A.4 - Administrative change - Change in the name 
23/02/2012 
n/a 
and/or address of a manufacturer or supplier of the 
AS, starting material, reagent or intermediate used 
in the manufacture of the AS 
IB/0016/G 
This was an application for a group of variations. 
26/01/2012 
26/07/2012 
SmPC and PL 
Following PhVWP/CHMP conclusions of June 2011 
update of the Summary of Product Characteristics 
(SrnPC) and Package Leaflet (PL) in line with the 
reference medicinal product regarding the use of 
antipsychotics during the third trimester of 
pregnancy and risk of abnormal muscle movements 
and/or withdrawal symptoms in newborns in 
accordance with the PhVWP/CHMP class labelling 
recommended wording. 
Following CHMP conclusions of October 2011 update 
of the SmPC and Package Leaflet in line with the 
reference medicinal product. Update of SmPC section 
4.4 to include metabolic monitoring frequency 
examples following the assessment of the Latest 
PSURs and RMP for the reference medicinal product. 
The Package Leaflet is updated accordingly. 
Update of the frequency of Venous thromboenibolism 
(VTE) in SmPC section 4.4 and 4.8 following PhVWP 
recommendation to include warnings about the risk 
of venous thromboembolism. The Package Leaflet is 
updated accordingly. 
Page 8/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corrections in the annexes have been proposed for 
the following countries: Bulgaria, Danemark, Czech 
Republic , Germany, Greece, Finland, Iceland, 
Norway, Portugal, Romania, Slovakia and Slovenia. 
These changes are in line with the reference 
medicinal product. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IAIN/0017 
B.II.b.1.a - Replacement or addition of a 
23/01/2012 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0015/G 
This was an application for a group of variations. 
24/11/2011 
26/07/2012 
Annex II and 
PL 
B.I.a.1.a - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
 
 
site 
B.II.b.2.b.1 - Change to batch release arrangements 
and quality control testing of the FP - Not including 
batch control/testing 
IB/0014 
B.I.a.1.z - Change in the manufacturer of AS or of a 
15/09/2011 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0013 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
16/03/2011 
n/a 
SmPC and 
life of the finished product - As packaged for sale 
Annex II 
(supported by real time data) 
IB/0012 
Update of sections 4.4 (deletion of a sentence in the 
26/10/2010 
n/a 
SmPC and PL 
warning related to hepatic function) and 4.8 
(modification of the prolactin information in the 
footnote) of the Summary of Product Characteristics 
resulting of a review of the company core data sheet. 
Additional changes were made to the Product 
Information and Annex II in accordance with the 
QRD templates (version 7.3.1.). 
At the same time MAH takes the opportunity to 
change telephone number for Latvia in the list of 
local representative of the Marketing Authorisation 
Holder. We also made minor QRD corrections in all 
translations and minor editorial changes in Danish, 
French, Dutch and Slovenian texts. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
IB/0011 
Update of the sections 4.8 and 4.4 of the Summary 
31/03/2010 
n/a 
SmPC and PL 
of Product Characteristics (SPC) in line with the 
Product Information of the reference product 
regarding sudden cardiac death, urinary incontinence 
and information on elevated plasma prolactin 
concentrations and related clinical manifestations. 
Section 4 of the package leaflet has also been 
amended accordingly. Minor editorial changes were 
made to the EL annexes. Furthermore the details of 
the local representatives in the United Kingdom, 
Cyprus, Austria, Romania, Bulgaria, Estonia, Czech 
Republic, Hungary, Lithuania, Slovakia, France, 
Ireland, Malta, Portugal, Poland, Spain and Slovenia 
were updated. Additionally, editorial changes were 
made in the relevant sections of the Product 
Information. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data are submitted by the MAH 
II/0009 
Update to section 4.8 of the Summary of Product 
24/09/2009 
30/10/2009 
SmPC 
The SPC was updated to align it with that of the reference 
Characteristics (SPC) in line with the Product 
Information of the reference medicinal products. An 
editorial change was made in section 4.4 of the SPC. 
medicinal products. This followed a change to the SPC of 
the reference medicinal products via the following 
procedures: Zyprexa (EMEA/H/C/000115/II/0099) and 
Zyprexa Velotab (EMEA/H/C/000287/II/0070). 
Page 11/14 
 
 
 
 
 
 
 
 
 
 
Update of Summary of Product Characteristics 
II/0007 
Update to sections 4.4, 4.9 and 5.1 of the Summary 
25/06/2009 
17/07/2009 
SmPC and PL 
Following changes to the SPC of the reference medicinal 
of Product Characteristics (SPC) in line with the 
reference medicinal product Zyprexa, and update to 
the Package Leaflet regarding the contact details for 
the local representatives for Cyprus and Greece. 
Update of Summary of Product Characteristics and 
Package Leaflet 
product Zyprexa, sections 4.4, 4.9 and 5.1 of the Zalasta 
SPC were updated. Recommendations on monitoring of 
patients for signs and symptoms of hyperglycaemia, 
worsening of glucose control and weight gain were added 
to section 4.4 and new information on acute overdose was 
added to section 4.9. Section 5.1 of the SPC was also 
updated with regard to the details of the ATC code. The 
contact details of the local representatives for Cyprus and 
Greece was updated in the Package Leaflet. 
The summary of the above mentioned changes may be 
found in the EPARs (module 8B) of Zyprexa (II/96) and 
Zyprexa Velotab (II/68). 
IA/0008 
IA_07_a_Replacement/add. of manufacturing site: 
15/05/2009 
n/a 
Secondary packaging site 
II/0006 
Update of Section 4.8 of the SPC in line with the 
23/10/2008 
26/11/2008 
SmPC 
Following a change to the SPC of the reference medicinal 
reference medicinal product. Some minor editorial 
changes have been introduced to keep the SPC in 
line with that for the reference product. 
Update of Summary of Product Characteristics 
product, Section 4.8 of the SPC of Zalasta were updated to 
align them with those of the reference medicinal product to 
include new data regarding changes in bodyweight, glucose 
and lipid levels over time in adults and adolescents. 
The summary of the above mentioned changes may be 
found in the EPARs (module 8B) of Zyprexa (II/92) and 
Zyprexa Velotab (II/61). 
II/0005 
Update of Sections 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of 
24/07/2008 
22/08/2008 
SmPC, Annex 
Following a change to the SPC of the reference medicinal 
the SPC in line with the reference medicinal product. 
II and PL 
product, Sections 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SPC 
The Product Information was updated in accordance 
of Zalasta were updated to align them with those of the 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
with the latest QRD templates. 
Update of Summary of Product Characteristics and 
Package Leaflet 
reference medicinal product to include data from studies 
conducted in adolescent population with schizophrenia and 
bipolar I disorder (manic or mixed episodes).  
The summary of the above mentioned changes may be 
found in the EPARs (module 8B) of Zyprexa (II/83) and 
Zyprexa Velotab (II/52). 
II/0004 
Update of section 4.4 and 4.8 of Summary of Product 
30/05/2008 
08/07/2008 
SmPC and PL 
Following changes to the SPC and PL of the reference 
Characteristics (SPC) and relevant section of the 
Package Leaflet (PL). 
medicinal product, the SPC and PL of Zalasta were updated 
to align it with that of the reference medicinal product. 
Update of Summary of Product Characteristics and 
Both existing warnings on diabetes and lipids alterations in 
Package Leaflet 
section 4.4 of the SPC have been updated. In addition, 
section 4.8 of the SPC was amended to add the term 
"glycosuria" as commonly occurring event, to amend the 
frequency of hyperglycaemia from very rare to rare, and to 
add further information in relation to weight gain, elevated 
glucose levels, elevated triglyceride levels and elevated 
cholesterol levels. The Package Leaflet was amended 
accordingly. 
II/0003 
Update of section 4.8 of the Summary of Product 
21/02/2008 
02/04/2008 
SmPC 
Following a change to the SPC of the reference medicinal 
Characteristics (SPC) in line with the reference 
medicinal product. 
Update of Summary of Product Characteristics 
product, the SPC of Zalasta was updated to align it with 
that of the reference medicinal product. Section 4.8 was 
updated to include 'fatigue'. 
N/0001 
Update of the local representative in Germany in 
11/01/2008 
n/a 
PL 
section 6 of the Package Leaflet. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0002 
IA_32_b_Change in batch size of the finished 
05/12/2007 
n/a 
product - downscaling down to 10-fold 
Page 14/14 
 
 
 
 
 
 
 
 
 
 
